(Q45901690)

English

The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.

scientific article published on 15 December 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

Claudia Durán-Aniotz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Diego Francisco Catalán

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Lorena Salazar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristián Pereda

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristián Falcón

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Fabián Tempio

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Raquel Aguilera

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rodrigo González

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Claudio Pérez

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Andrés Tittarelli

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bruno Nervi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Milton Larrondo

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Flavio Salazar-Onfray

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mercedes N López

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

15 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

62

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

761-772

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

https://scigraph.springernature.com/pub.10.1007/s00262-012-1377-3

0 references

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Immunotherapy for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The first 1000 dendritic cell vaccinees.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells: immunobiology and cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Assessing oncologic benefit in clinical trials of immunotherapy agents

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Cancer immunology--analysis of host and tumor factors for personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Importance of CD4(+) T helper cell responses in tumor immunity.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor-specific Th17-polarized cells eradicate large established melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The polarization of immune cells in the tumour environment by TGFbeta

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Deciphering the role of Th17 cells in human disease

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The roles of IFN gamma in protection against tumor development and cancer immunoediting

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Identifiers

10.1007/S00262-012-1377-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45901690&oldid=1242740365"